Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis

NCT01265667 is registered in ClinicalTrials.gov with Can-Fite BioPharma as lead sponsor.

NCT NCT01265667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01265667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Can-Fite BioPharma
Phase
Phase 2/3
Overall status
Completed
Start date
July 31, 2011
Completion date
May 31, 2015
Enrollment
293 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis